PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a double-blinded, placebo-controlled, dose-escalating study (NCT06138743) to evaluate single and multiple ascending doses of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic, in up to 48 subjects with type 1 myotonic dystrophy (DM1). DM1 is the most common adult-onset muscular dystrophy. Patients with DM1 have muscle weakness and wast ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen's 44th Annual Health Care Conference – March 6, 2024 Type: Fireside Chat Presentation Date: March 6, 2024 Time: 9:10 a.m. ET Leerink Partners Global Biopharma Conference – March 13, 2024 Type: Fireside Chat Presentation Date: March 13, 2024 Time: 8:00 a.m. ET Presentation materials may be accessed on the Events and Presentations ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _____________________________________ ARROWHEAD ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of ...

icarus666/Moment via Getty Images In my coverage of Arrowhead Pharmaceuticals (ARWR) last February, I noted that my primary problem with ARWR is a lack of focus. Just look at this pipeline: ARWR PIPELINE (ARWR WEBSITE) There are, if I am counting it right, some 16 programs in the clinic, and frankly, this is too much. Like I noted last time, they should probably have focused on getting one product through the finishing line. Then, this long-tailed pipeline would have been an asset. If you want a good tail, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Conference Call November 29, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Chief Financial Officer Tracy Oliver - Chief Commercial Officer Patrick O'Brien - Chief Operating Officer and General Counsel Conference Call Participants Edward ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-K __________________________________________________________________ (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 ________ ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Chief Financial Officer Conference Call Participants Luca Issi - RBC Capital Maury Raycroft - Jefferies Patrick Trucchio - HC Wainwright & Company Keay Nakae - Char ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-38042 _____________________________________ ARROWHEAD PH ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Vincent Anzalone - Vice President, Investor Relations Christopher Anzalone - President and Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief, Discovery and Translational Medicine Ken Myszkowski - Chief Financial Officer Conference Call Participants Maury Raycroft - Jefferies Eliana Mural - UBS Joel Beatty - Baird Mani Foroohar - SVB Mayank Mamtani ...